Results 211 to 220 of about 384,579 (349)

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy

open access: yesBMEMat, EarlyView.
The immunosuppressive tumor microenvironment, characterized by hypoxia, redox imbalance, elevated interstitial fluid pressure, and acidity, was comprehensively elucidated. This review discussed the etiology and consequences of the characteristics of the immunosuppressive tumor microenvironment, and analyzed the recent advancements in nanomaterials for ...
Wen Zhang   +7 more
wiley   +1 more source

The Tumor Suppressor p53 and Histone Deacetylase 1 Are Antagonistic Regulators of the Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 Gene [PDF]

open access: bronze, 2003
G. Lagger   +10 more
openalex   +1 more source

Dynamics of natural killer cell function upon recurrent stimulation

open access: yesBiotechnology Progress, EarlyView.
Weekly stimulation of peripheral blood‐derived NK cells with engineered K562 feeder cells resulted in two distinct growth phases, shifting around Day 21–26. Cells in growth phase 2 exhibited slower growth, reduced metabolic activity, and lower cytotoxicity than cells from growth phase 1, which has implications for NK cell biomanufacturing.
Jennifer One   +4 more
wiley   +1 more source

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Emmanuel Chigutsa   +2 more
wiley   +1 more source

EGR1 Nuclear Condensates Promote Renal Cyst Development in Polycystic Kidney Disease

open access: yesExploration, EarlyView.
ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is marked by aberrant cell proliferation driven by cAMP‐PKA and MAPK signaling pathways. EGR1, a transcription factor directly activated by the above two pathways, is critical in the over‐proliferation of tumor cells, which share similarities with cystic epithelial cells in ADPKD. This study
Chaoqun Ren   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy